Growth Factor Analog

PEG-MGF

Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

What is PEG-MGF?

FDA says compounded PEG-MGF may pose immunogenicity, impurity, and characterization risks and that it has identified no human exposure data for PEG-MGF administered by any route.

Dosing as published

No approved-label or study protocol is recorded for PEG-MGF yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (3)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingFDA has announced a Pharmacy Compounding Advisory Committee review before the end of February 2027; review is not approval
Last checked2026-07-13
Next review2026-10-11

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.